Skip to main content
SpringerLink
Log in

Lung Cancer Prevention

  • Chapter
  • First Online:
Book cover Lung Cancer

Part of the book series: Current Clinical Oncology ((CCO))

  • 2495 Accesses

Abstract

The poor prognosis associated with lung cancer has stimulated substantial effort directed toward lung cancer prevention. As smoking prevention and cessation have proven difficult to achieve, many chemoprevention trials have been done during the last few decades. Such trials have focused on lung cancer survivors and high-risk groups including current and former heavy smokers with or without COPD. The aims of these trials were to reduce lung cancer incidence as well as to reduce/reverse premalignant changes in the bronchial epithelium. Unfortunately, till now all the chemoprevention clinical trials have failed to show any clinical or histologic benefit with respect to lung cancer.

This chapter reviews the chemoprevention trials that have been done in the last few decades, analyzes the reasons for their failure, and reviews the future directions and the targeted therapy that may be potentially relevant in the chemoprevention of lung cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 279.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Spitz MR, Hsu TC, Wu X, Fueger JJ, Amos CI, Roth JA (1995) Mutagen sensitivity as a biological marker of lung cancer risk in African Americans. Cancer Epidemiol Biomarkers Prev 4(2):99-103

    PubMed  CAS  Google Scholar 

  2. Sporn MB, Dunlop NM, Newton DL, Smith JM (1976) Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed Proc 35(6):1332-1338

    PubMed  CAS  Google Scholar 

  3. (1994) The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. N Engl J Med 330(15):1029-1035

    Google Scholar 

  4. Hennekens CH, Buring JE, Manson JE et al (1996) Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 334(18):1145-1149

    PubMed  CAS  Google Scholar 

  5. Omenn GS, Goodman GE, Thornquist MD et al (1996) Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 334(18):1150-1155

    PubMed  CAS  Google Scholar 

  6. van Zandwijk N, Dalesio O, Pastorino U, de Vries N, van Tinteren H (2000) EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. For the EUropean Organization for Research and Treatment of Cancer Head and Neck and Lung Cancer Cooperative Groups. J Natl Cancer Inst 92(12):977-986

    PubMed  Google Scholar 

  7. Muscat JE, Chen SQ, Richie JP Jr et al (2003) Risk of lung carcinoma among users of nonsteroidal antiinflammatory drugs. Cancer 97(7):1732-1736

    PubMed  Google Scholar 

  8. Hirsch FR, Lippman SM (2005) Advances in the biology of lung cancer chemoprevention. J Clin Oncol 23(14):3186-3197

    PubMed  CAS  Google Scholar 

  9. Rao CV, Reddy BS (2004) NSAIDs and chemoprevention. Curr Cancer Drug Targets 4(1):29-42

    PubMed  CAS  Google Scholar 

  10. Williams CS, Mann M, DuBois RN (1999) The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 18(55):7908-7916

    PubMed  CAS  Google Scholar 

  11. Khuri FR, Wu H, Lee JJ et al (2001) Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin Cancer Res 7(4):861-867

    PubMed  CAS  Google Scholar 

  12. Hida T, Yatabe Y, Achiwa H et al (1998) Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 58(17):3761-3764

    PubMed  CAS  Google Scholar 

  13. Steinbach G, Lynch PM, Phillips RK et al (2000) The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342(26):1946-1952

    PubMed  CAS  Google Scholar 

  14. Bardou M, Barkun AN, Ghosn J, Hudson M, Rahme E (2004) Effect of chronic intake of NSAIDs and cyclooxygenase 2-selective inhibitors on esophageal cancer incidence. Clin Gastroenterol Hepatol 2(10):880-887

    PubMed  CAS  Google Scholar 

  15. Reddy BS, Hirose Y, Lubet R et al (2000) Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res 60(2):293-297

    PubMed  CAS  Google Scholar 

  16. Hu PJ, Yu J, Zeng ZR et al (2004) Chemoprevention of gastric cancer by celecoxib in rats. Gut 53(2):195-200

    PubMed  CAS  Google Scholar 

  17. Diperna CA, Bart RD, Sievers EM, Ma Y, Starnes VA, Bremner RM (2003) Cyclooxygenase-2 inhibition decreases primary and metastatic tumor burden in a murine model of orthotopic lung adenocarcinoma. J Thorac Cardiovasc Surg 126(4):1129-1133

    PubMed  CAS  Google Scholar 

  18. Klenke FM, Gebhard MM, Ewerbeck V, Abdollahi A, Huber PE, Sckell A (2006) The selective Cox-2 inhibitor Celecoxib suppresses angiogenesis and growth of secondary bone tumors: an intravital microscopy study in mice. BMC Cancer 6:9

    PubMed  Google Scholar 

  19. Harris RE, Alshafie GA, Abou-Issa H, Seibert K (2000) Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res 60(8):2101-2103

    PubMed  CAS  Google Scholar 

  20. Li N, Sood S, Wang S et al (2005) Overexpression of 5-lipoxygenase and cyclooxygenase 2 in hamster and human oral cancer and chemopreventive effects of zileuton and celecoxib. Clin Cancer Res 11(5):2089-2096

    PubMed  CAS  Google Scholar 

  21. Gupta S, Adhami VM, Subbarayan M et al (2004) Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model. Cancer Res 64(9):3334-3343

    PubMed  CAS  Google Scholar 

  22. Grubbs CJ, Lubet RA, Koki AT et al (2000) Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. Cancer Res 60(20):5599-5602

    PubMed  CAS  Google Scholar 

  23. Fischer SM, Lo HH, Gordon GB et al (1999) Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis. Mol Carcinog 25(4):231-240

    PubMed  CAS  Google Scholar 

  24. Mao JT, Cui X, Reckamp K et al (2005) Chemoprevention strategies with cyclooxygenase-2 inhibitors for lung cancer. Clin Lung Cancer 7(1):30-39

    PubMed  CAS  Google Scholar 

  25. Abou-Issa H, Alshafie G (2004) Celecoxib: a novel treatment for lung cancer. Expert Rev Anticancer Ther 4(5):725-734

    PubMed  CAS  Google Scholar 

  26. Hirsch FR, Franklin WA, Gazdar AF, Bunn PA Jr (2001) Early detection of lung cancer: clinical perspectives of recent advances in biology and radiology. Clin Cancer Res 7(1):5-22

    PubMed  CAS  Google Scholar 

  27. Nettesheim P, Marchok A (1983) Neoplastic development in airway epithelium. Adv Cancer Res 39:1-70

    PubMed  CAS  Google Scholar 

  28. Brambilla E, Travis WD, Colby TV, Corrin B, Shimosato Y (2001) The new World Health Organization classification of lung tumours. Eur Respir J 18(6):1059-1068

    PubMed  CAS  Google Scholar 

  29. Soria JC, Kim ES, Fayette J, Lantuejoul S, Deutsch E, Hong WK (2003) Chemoprevention of lung cancer. Lancet Oncol 4(11):659-669

    PubMed  CAS  Google Scholar 

  30. Omenn GS (1998) Chemoprevention of lung cancer: the rise and demise of beta-carotene. Annu Rev Public Health 19:73-99

    PubMed  CAS  Google Scholar 

  31. Johnson BE (1998) Second lung cancers in patients after treatment for an initial lung cancer. J Natl Cancer Inst 90(18):1335-1345

    PubMed  CAS  Google Scholar 

  32. Peled N, Flex D, Raviv Y et al (2009) The role of routine bronchoscopy for early detection of bronchial stump recurrence of lung cancer-1 year post-surgery. Lung Cancer 65(3):319-323

    PubMed  Google Scholar 

  33. Jemal A, Ward E, Hao Y, Thun M (2005) Trends in the leading causes of death in the United States, 1970-2002. JAMA 294(10):1255-1259

    PubMed  CAS  Google Scholar 

  34. Bach PB, Kelley MJ, Tate RC, McCrory DC (2003) Screening for lung cancer: a review of the current literature. Chest 123(1 Suppl):72S-82S

    PubMed  Google Scholar 

  35. Kennedy TC, Proudfoot SP, Franklin WA et al (1996) Cytopathological analysis of sputum in patients with airflow obstruction and significant smoking histories. Cancer Res 56(20):4673-4678

    PubMed  CAS  Google Scholar 

  36. Prindiville SA, Byers T, Hirsch FR et al (2003) Sputum cytological atypia as a predictor of incident lung cancer in a cohort of heavy smokers with airflow obstruction. Cancer Epidemiol Biomarkers Prev 12(10):987-993

    PubMed  Google Scholar 

  37. (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365(9472):1687-717

    Google Scholar 

  38. Wilson DO, Weissfeld JL, Balkan A et al (2008) Association of radiographic emphysema and airflow obstruction with lung cancer. Am J Respir Crit Care Med 178(7):738-744

    PubMed  Google Scholar 

  39. Ding L, Getz G, Wheeler DA et al (2008) Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455(7216):1069-1075

    PubMed  CAS  Google Scholar 

  40. Cassidy A, Myles JP, van Tongeren M et al (2008) The LLP risk model: an individual risk prediction model for lung cancer. Br J Cancer 98(2):270-276

    PubMed  CAS  Google Scholar 

  41. Sato M, Shames DS, Gazdar AF, Minna JD (2007) A translational view of the molecular pathogenesis of lung cancer. J Thorac Oncol 2(4):327-343

    PubMed  Google Scholar 

  42. Belinsky SA, Liechty KC, Gentry FD et al (2006) Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort. Cancer Res 66(6):3338-3344

    PubMed  CAS  Google Scholar 

  43. Phillips M, Gleeson K, Hughes JM et al (1999) Volatile organic compounds in breath as markers of lung cancer: a cross-sectional study. Lancet 353(9168):1930-1933

    PubMed  CAS  Google Scholar 

  44. Phillips M, Altorki N, Austin JH et al (2007) Prediction of lung cancer using volatile biomarkers in breath. Cancer Biomark 3(2):95-109

    PubMed  CAS  Google Scholar 

  45. Peng G, Trock E, Haick H (2008) Detecting simulated patterns of lung cancer biomarkers by random network of single-walled carbon nanotubes coated with nonpolymeric organic materials. Nano Lett 8(11):3631-3635

    PubMed  CAS  Google Scholar 

  46. Shopland DR, Eyre HJ, Pechacek TF (1991) Smoking-attributable cancer mortality in 1991: is lung cancer now the leading cause of death among smokers in the United States? J Natl Cancer Inst 83(16):1142-1148

    PubMed  CAS  Google Scholar 

  47. Perez-Padilla R, Regalado J, Vedal S et al (1996) Exposure to biomass smoke and chronic airway disease in Mexican women. A case-control study. Am J Respir Crit Care Med 154(3 Pt 1):701-706

    PubMed  CAS  Google Scholar 

  48. Delgado J, Martinez LM, Sanchez TT, Ramirez A, Iturria C, Gonzalez-Avila G (2005) Lung cancer pathogenesis associated with wood smoke exposure. Chest 128(1):124-131

    PubMed  CAS  Google Scholar 

  49. Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE (2005) The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 142(4):233-239

    PubMed  Google Scholar 

  50. Song YM, Sung J, Cho HJ (2008) Reduction and cessation of cigarette smoking and risk of cancer: a cohort study of Korean men. J Clin Oncol 26(31):5101-5106

    PubMed  Google Scholar 

  51. Tverdal A, Bjartveit K (2006) Health consequences of reduced daily cigarette consumption. Tob Control 15(6):472-480

    PubMed  Google Scholar 

  52. Eisenberg MJ, Filion KB, Yavin D et al (2008) Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials. CMAJ 179(2):135-144

    PubMed  Google Scholar 

  53. Gonzales D, Rennard SI, Nides M et al (2006) Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 296(1):47-55

    PubMed  CAS  Google Scholar 

  54. Jorenby DE, Hays JT, Rigotti NA et al (2006) Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 296(1):56-63

    PubMed  CAS  Google Scholar 

  55. Peto R, Darby S, Deo H, Silcocks P, Whitley E, Doll R (2000) Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies. BMJ 321(7257):323-329

    PubMed  CAS  Google Scholar 

  56. Tong L, Spitz MR, Fueger JJ, Amos CA (1996) Lung carcinoma in former smokers. Cancer 78(5):1004-1010

    PubMed  CAS  Google Scholar 

  57. Kelloff GJ, Lippman SM, Dannenberg AJ et al (2006) Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer - a plan to move forward. Clin Cancer Res 12(12):3661-3697

    PubMed  CAS  Google Scholar 

  58. Kelloff GJ, Sigman CC (2007) Assessing intraepithelial neoplasia and drug safety in cancer-preventive drug development. Nat Rev Cancer 7(7):508-518

    PubMed  CAS  Google Scholar 

  59. Lam S, Kennedy T, Unger M et al (1998) Localization of bronchial intraepithelial neoplastic lesions by fluorescence bronchoscopy. Chest 113(3):696-702

    PubMed  CAS  Google Scholar 

  60. Lam S, MacAulay C, leRiche JC, Palcic B (2000) Detection and localization of early lung cancer by fluorescence bronchoscopy. Cancer 89(11 Suppl):2468-2473

    PubMed  CAS  Google Scholar 

  61. Bota S, Auliac JB, Paris C et al (2001) Follow-up of bronchial precancerous lesions and carcinoma in situ using fluorescence endoscopy. Am J Respir Crit Care Med 164(9):1688-1693

    PubMed  CAS  Google Scholar 

  62. Venmans BJ, van Boxem TJ, Smit EF, Postmus PE, Sutedja TG (2000) Outcome of bronchial carcinoma in situ. Chest 117(6):1572-1576

    PubMed  CAS  Google Scholar 

  63. Westra WH (2000) Early glandular neoplasia of the lung. Respir Res 1(3):163-169

    PubMed  CAS  Google Scholar 

  64. Beasley MB, Brambilla E, Travis WD (2005) The 2004 World Health Organization classification of lung tumors. Semin Roentgenol 40(2):90-97

    PubMed  Google Scholar 

  65. Ikeda K, Nomori H, Ohba Y et al (2008) Epidermal growth factor receptor mutations in multicentric lung adenocarcinomas and atypical adenomatous hyperplasias. J Thorac Oncol 3(5):467-471

    PubMed  Google Scholar 

  66. Licchesi JD, Westra WH, Hooker CM, Herman JG (2008) Promoter hypermethylation of hallmark cancer genes in atypical adenomatous hyperplasia of the lung. Clin Cancer Res 14(9):2570-2578

    PubMed  CAS  Google Scholar 

  67. Licchesi JD, Westra WH, Hooker CM, Machida EO, Baylin SB, Herman JG (2008) Epigenetic alteration of Wnt pathway antagonists in progressive glandular neoplasia of the lung. Carcinogenesis 29(5):895-904

    PubMed  CAS  Google Scholar 

  68. Lee JS, Lippman SM, Benner SE et al (1994) Randomized placebo-controlled trial of isotretinoin in chemoprevention of bronchial squamous metaplasia. J Clin Oncol 12(5):937-945

    PubMed  CAS  Google Scholar 

  69. Lippman SM, Benner SE, Hong WK (1994) Cancer chemoprevention. J Clin Oncol 12(4):851-873

    PubMed  CAS  Google Scholar 

  70. McLarty JW, Holiday DB, Girard WM, Yanagihara RH, Kummet TD, Greenberg SD (1995) Beta-Carotene, vitamin A, and lung cancer chemoprevention: results of an intermediate endpoint study. Am J Clin Nutr 62(6 Suppl):1431S-1438S

    PubMed  CAS  Google Scholar 

  71. Kurie JM, Lee JS, Khuri FR et al (2000) N-(4-hydroxyphenyl)retinamide in the chemoprevention of squamous metaplasia and dysplasia of the bronchial epithelium. Clin Cancer Res 6(8):2973-2979

    PubMed  CAS  Google Scholar 

  72. Lam S, MacAulay C, Le Riche JC et al (2002) A randomized phase IIb trial of anethole dithiolethione in smokers with bronchial dysplasia. J Natl Cancer Inst 94(13):1001-1009

    PubMed  CAS  Google Scholar 

  73. Kurie JM, Lotan R, Lee JJ et al (2003) Treatment of former smokers with 9-cis-retinoic acid reverses loss of retinoic acid receptor-beta expression in the bronchial epithelium: results from a randomized placebo-controlled trial. J Natl Cancer Inst 95(3):206-214

    PubMed  CAS  Google Scholar 

  74. Lam S, Xu X, Parker-Klein H et al (2003) Surrogate end-point biomarker analysis in a retinol chemoprevention trial in current and former smokers with bronchial dysplasia. Int J Oncol 23(6):1607-1613

    PubMed  CAS  Google Scholar 

  75. Lam S, leRiche JC, McWilliams A et al (2004) A randomized phase IIb trial of pulmicort turbuhaler (budesonide) in people with dysplasia of the bronchial epithelium. Clin Cancer Res 10(19):6502-6511

    PubMed  CAS  Google Scholar 

  76. Lippman SM, Lee JJ, Karp DD et al (2001) Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer. J Natl Cancer Inst 93(8):605-618

    PubMed  CAS  Google Scholar 

  77. Lippman SM, Klein EA, Goodman PJ et al (2009) Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 301(1):39-51

    PubMed  CAS  Google Scholar 

  78. Lippman SM, Kessler JF, Meyskens FL Jr (1987) Retinoids as preventive and therapeutic anticancer agents (Part II). Cancer Treat Rep 71(5):493-515

    PubMed  CAS  Google Scholar 

  79. Brabender J, Metzger R, Salonga D et al (2005) Comprehensive expression analysis of retinoic acid receptors and retinoid X receptors in non-small cell lung cancer: implications for tumor development and prognosis. Carcinogenesis 26(3):525-530

    PubMed  CAS  Google Scholar 

  80. Lotan R, Xu XC, Lippman SM et al (1995) Suppression of retinoic acid receptor-beta in premalignant oral lesions and its up-regulation by isotretinoin. N Engl J Med 332(21):1405-1410

    PubMed  CAS  Google Scholar 

  81. Lotan R (2005) A crucial role for cellular retinol-binding protein I in retinoid signaling. J Natl Cancer Inst 97(1):3-4

    PubMed  Google Scholar 

  82. Srinivas H, Juroske DM, Kalyankrishna S et al (2005) c-Jun N-terminal kinase contributes to aberrant retinoid signaling in lung cancer cells by phosphorylating and inducing proteasomal degradation of retinoic acid receptor alpha. Mol Cell Biol 25(3):1054-1069

    PubMed  CAS  Google Scholar 

  83. Vourlekis JS, Szabo E (2003) Predicting success in cancer prevention trials. J Natl Cancer Inst 95(3):178-179

    PubMed  Google Scholar 

  84. Khuri FR, Lotan R, Kemp BL et al (2000) Retinoic acid receptor-beta as a prognostic indicator in stage I non-small-cell lung cancer. J Clin Oncol 18(15):2798-2804

    PubMed  CAS  Google Scholar 

  85. Soria JC, Xu X, Liu DD et al (2003) Retinoic acid receptor beta and telomerase catalytic subunit expression in bronchial epithelium of heavy smokers. J Natl Cancer Inst 95(2):165-168

    PubMed  CAS  Google Scholar 

  86. Kim JS, Lee H, Kim H et al (2004) Promoter methylation of retinoic acid receptor beta 2 and the development of second primary lung cancers in non-small-cell lung cancer. J Clin Oncol 22(17):3443-3450

    PubMed  CAS  Google Scholar 

  87. Berard J, Laboune F, Mukuna M, Masse S, Kothary R, Bradley WE (1996) Lung tumors in mice expressing an antisense RARbeta2 transgene. FASEB J 10(9):1091-1097

    PubMed  CAS  Google Scholar 

  88. Xu XC, Lee JJ, Wu TT, Hoque A, Ajani JA, Lippman SM (2005) Increased retinoic acid receptor-beta4 correlates in vivo with reduced retinoic acid receptor-beta2 in esophageal squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 14(4):826-829

    PubMed  CAS  Google Scholar 

  89. Albanes D (2009) Vitamin supplements and cancer prevention: where do randomized controlled trials stand? J Natl Cancer Inst 101(1):2-4

    PubMed  CAS  Google Scholar 

  90. Hennekens CH, Buring JE, Peto R (1994) Antioxidant vitamins - benefits not yet proved. N Engl J Med 330(15):1080-1081

    PubMed  CAS  Google Scholar 

  91. Virtamo J, Pietinen P, Huttunen JK et al (2003) Incidence of cancer and mortality following alpha-tocopherol and beta-carotene supplementation: a postintervention follow-up. JAMA 290(4):476-485

    PubMed  CAS  Google Scholar 

  92. Lippman SM, Goodman PJ, Klein EA et al (2005) Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). J Natl Cancer Inst 97(2):94-102

    PubMed  CAS  Google Scholar 

  93. Ghosh J (2004) Rapid induction of apoptosis in prostate cancer cells by selenium: reversal by metabolites of arachidonate 5-lipoxygenase. Biochem Biophys Res Commun 315(3):624-635

    PubMed  CAS  Google Scholar 

  94. Clark LC, Combs GF Jr, Turnbull BW et al (1996) Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 276(24):1957-1963

    PubMed  CAS  Google Scholar 

  95. Reid ME, Duffield-Lillico AJ, Garland L, Turnbull BW, Clark LC, Marshall JR (2002) Selenium supplementation and lung cancer incidence: an update of the nutritional prevention of cancer trial. Cancer Epidemiol Biomarkers Prev 11(11):1285-1291

    PubMed  CAS  Google Scholar 

  96. Zhuo H, Smith AH, Steinmaus C (2004) Selenium and lung cancer: a quantitative analysis of heterogeneity in the current epidemiological literature. Cancer Epidemiol Biomarkers Prev 13(5):771-778

    PubMed  CAS  Google Scholar 

  97. Shureiqi I, Lippman SM (2001) Lipoxygenase modulation to reverse carcinogenesis. Cancer Res 61(17):6307-6312

    PubMed  CAS  Google Scholar 

  98. Muller R (2004) Crosstalk of oncogenic and prostanoid signaling pathways. J Cancer Res Clin Oncol 130(8):429-444

    PubMed  Google Scholar 

  99. Meyer AM, Dwyer-Nield LD, Hurteau GJ et al (2004) Decreased lung tumorigenesis in mice genetically deficient in cytosolic phospholipase A2. Carcinogenesis 25(8):1517-1524

    PubMed  CAS  Google Scholar 

  100. Riedl K, Krysan K, Pold M et al (2004) Multifaceted roles of cyclooxygenase-2 in lung cancer. Drug Resist Updat 7(3):169-184

    PubMed  CAS  Google Scholar 

  101. Yamaki T, Endoh K, Miyahara M et al (2004) Prostaglandin E2 activates Src signaling in lung adenocarcinoma cell via EP3. Cancer Lett 214(1):115-120

    PubMed  CAS  Google Scholar 

  102. Shishodia S, Aggarwal BB (2004) Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates activation of cigarette smoke-induced nuclear factor (NF)-kappaB by suppressing activation of IkappaBalpha kinase in human non-small cell lung carcinoma: correlation with suppression of cyclin D1, COX-2, and matrix metalloproteinase-9. Cancer Res 64(14):5004-5012

    PubMed  CAS  Google Scholar 

  103. Kisley LR, Barrett BS, Dwyer-Nield LD, Bauer AK, Thompson DC, Malkinson AM (2002) Celecoxib reduces pulmonary inflammation but not lung tumorigenesis in mice. Carcinogenesis 23(10):1653-1660

    PubMed  CAS  Google Scholar 

  104. Edelman MJ, Watson D, Wang X et al (2008) Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy - Cancer and Leukemia Group B Trial 30203. J Clin Oncol 26(6):848-855

    PubMed  CAS  Google Scholar 

  105. Mao JT, Fishbein MC, Adams B et al (2006) Celecoxib decreases Ki-67 proliferative index in active smokers. Clin Cancer Res 12(1):314-320

    PubMed  CAS  Google Scholar 

  106. Nie D, Lamberti M, Zacharek A et al (2000) Thromboxane A(2) regulation of endothelial cell migration, angiogenesis, and tumor metastasis. Biochem Biophys Res Commun 267(1):245-251

    PubMed  CAS  Google Scholar 

  107. Keith RL, Miller YE, Hudish TM et al (2004) Pulmonary prostacyclin synthase overexpression chemoprevents tobacco smoke lung carcinogenesis in mice. Cancer Res 64(16):5897-5904

    PubMed  CAS  Google Scholar 

  108. Zhou W, Hashimoto K, Goleniewska K et al (2007) Prostaglandin I2 analogs inhibit proinflammatory cytokine production and T cell stimulatory function of dendritic cells. J Immunol 178(2):702-710

    PubMed  CAS  Google Scholar 

  109. Nana-Sinkam SP, Lee JD, Sotto-Santiago S et al (2007) Prostacyclin prevents pulmonary endothelial cell apoptosis induced by cigarette smoke. Am J Respir Crit Care Med 175(7):676-685

    PubMed  CAS  Google Scholar 

  110. Ding Y, Tong M, Liu S, Moscow JA, Tai HH (2005) NAD+-linked 15-hydroxyprostaglandin dehydrogenase (15-PGDH) behaves as a tumor suppressor in lung cancer. Carcinogenesis 26(1):65-72

    PubMed  CAS  Google Scholar 

  111. Backlund MG, Mann JR, Holla VR et al (2005) 15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer. J Biol Chem 280(5):3217-3223

    PubMed  CAS  Google Scholar 

  112. Huang G, Eisenberg R, Yan M et al (2008) 15-Hydroxyprostaglandin dehydrogenase is a target of hepatocyte nuclear factor 3beta and a tumor suppressor in lung cancer. Cancer Res 68(13):5040-5048

    PubMed  CAS  Google Scholar 

  113. Rioux N, Castonguay A (1998) Prevention of NNK-induced lung tumorigenesis in A/J mice by acetylsalicylic acid and NS-398. Cancer Res 58(23):5354-5360

    PubMed  CAS  Google Scholar 

  114. Gunning WT, Kramer PM, Steele VE, Pereira MA (2002) Chemoprevention by lipoxygenase and leukotriene pathway inhibitors of vinyl carbamate-induced lung tumors in mice. Cancer Res 62(15):4199-4201

    PubMed  CAS  Google Scholar 

  115. Schroeder CP, Yang P, Newman RA, Lotan R (2007) Simultaneous inhibition of COX-2 and 5-LOX activities augments growth arrest and death of premalignant and malignant human lung cell lines. J Exp Ther Oncol 6(3):183-192

    PubMed  CAS  Google Scholar 

  116. Mao JT, Tsu IH, Dubinett SM et al (2004) Modulation of pulmonary leukotriene B4 production by cyclooxygenase-2 inhibitors and lipopolysaccharide. Clin Cancer Res 10(20):6872-6878

    PubMed  CAS  Google Scholar 

  117. Mao JT, Roth MD, Serio KJ et al (2003) Celecoxib modulates the capacity for prostaglandin E2 and interleukin-10 production in alveolar macrophages from active smokers. Clin Cancer Res 9(16 Pt 1):5835-5841

    PubMed  CAS  Google Scholar 

  118. Ye YN, Liu ES, Shin VY, Wu WK, Cho CH (2004) The modulating role of nuclear factor-kappaB in the action of alpha7-nicotinic acetylcholine receptor and cross-talk between 5-lipoxygenase and cyclooxygenase-2 in colon cancer growth induced by 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone. J Pharmacol Exp Ther 311(1):123-130

    PubMed  CAS  Google Scholar 

  119. Hong J, Bose M, Ju J et al (2004) Modulation of arachidonic acid metabolism by curcumin and related beta-diketone derivatives: effects on cytosolic phospholipase A(2), cyclooxygenases and 5-lipoxygenase. Carcinogenesis 25(9):1671-1679

    PubMed  CAS  Google Scholar 

  120. Ju J, Liu Y, Hong J, Huang MT, Conney AH, Yang CS (2003) Effects of green tea and high-fat diet on arachidonic acid metabolism and aberrant crypt foci formation in an azoxymethane-induced colon carcinogenesis mouse model. Nutr Cancer 46(2):172-178

    PubMed  CAS  Google Scholar 

  121. Yu R, Jiao JJ, Duh JL, Gudehithlu K, Tan TH, Kong AN (1997) Activation of mitogen-activated protein kinases by green tea polyphenols: potential signaling pathways in the regulation of antioxidant-responsive element-mediated phase II enzyme gene expression. Carcinogenesis 18(2):451-456

    PubMed  CAS  Google Scholar 

  122. Chen YQ, Duniec ZM, Liu B et al (1994) Endogenous 12(S)-HETE production by tumor cells and its role in metastasis. Cancer Res 54(6):1574-1579

    PubMed  CAS  Google Scholar 

  123. Grossi IM, Fitzgerald LA, Umbarger LA et al (1989) Bidirectional control of membrane expression and/or activation of the tumor cell IRGpIIb/IIIa receptor and tumor cell adhesion by lipoxygenase products of arachidonic acid and linoleic acid. Cancer Res 49(4):1029-1037

    PubMed  CAS  Google Scholar 

  124. Shureiqi I, Jiang W, Zuo X et al (2003) The 15-lipoxygenase-1 product 13-S-hydroxyoctadecadienoic acid down-regulates PPAR-delta to induce apoptosis in colorectal cancer cells. Proc Natl Acad Sci USA 100(17):9968-9973

    PubMed  CAS  Google Scholar 

  125. Hsi LC, Xi X, Lotan R, Shureiqi I, Lippman SM (2004) The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis via induction of 15-lipoxygenase-1 in colorectal cancer cells. Cancer Res 64(23):8778-8781

    PubMed  CAS  Google Scholar 

  126. Gonzalez AL, Roberts RL, Massion PP, Olson SJ, Shyr Y, Shappell SB (2004) 15-Lipoxygenase-2 expression in benign and neoplastic lung: an immunohistochemical study and correlation with tumor grade and proliferation. Hum Pathol 35(7):840-849

    PubMed  CAS  Google Scholar 

  127. Kudryavtsev IA, Golenko OD, Gudkova MV, Myasishcheva NV (2002) Arachidonic acid metabolism in growth control of A549 human lung adenocarcinoma cells. Biochemistry (Mosc) 67(9):1021-1026

    CAS  Google Scholar 

  128. Shankaranarayanan P, Nigam S (2003) IL-4 induces apoptosis in A549 lung adenocarcinoma cells: evidence for the pivotal role of 15-hydroxyeicosatetraenoic acid binding to activated peroxisome proliferator-activated receptor gamma transcription factor. J Immunol 170(2):887-894

    PubMed  CAS  Google Scholar 

  129. Spanbroek R, Hildner M, Kohler A et al (2001) IL-4 determines eicosanoid formation in dendritic cells by down-regulation of 5-lipoxygenase and up-regulation of 15-lipoxygenase 1 expression. Proc Natl Acad Sci USA 98(9):5152-5157

    PubMed  CAS  Google Scholar 

  130. Profita M, Sala A, Siena L et al (2002) Leukotriene B4 production in human mononuclear phagocytes is modulated by interleukin-4-induced 15-lipoxygenase. J Pharmacol Exp Ther 300(3):868-875

    PubMed  CAS  Google Scholar 

  131. Munger KA, Montero A, Fukunaga M et al (1999) Transfection of rat kidney with human 15-lipoxygenase suppresses inflammation and preserves function in experimental glomerulonephritis. Proc Natl Acad Sci USA 96(23):13375-13380

    PubMed  CAS  Google Scholar 

  132. Cappuzzo F, Hirsch FR, Rossi E et al (2005) Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 97(9):643-655

    PubMed  CAS  Google Scholar 

  133. Merrick DT, Kittelson J, Winterhalder R et al (2006) Analysis of c-ErbB1/epidermal growth factor receptor and c-ErbB2/HER-2 expression in bronchial dysplasia: evaluation of potential targets for chemoprevention of lung cancer. Clin Cancer Res 12(7 Pt 1):2281-2288

    PubMed  CAS  Google Scholar 

  134. Dannenberg AJ, Lippman SM, Mann JR, Subbaramaiah K, DuBois RN (2005) Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J Clin Oncol 23(2):254-266

    PubMed  CAS  Google Scholar 

  135. Chen Z, Zhang X, Li M et al (2004) Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck. Clin Cancer Res 10(17):5930-5939

    PubMed  CAS  Google Scholar 

  136. Lonardo F, Dragnev KH, Freemantle SJ et al (2002) Evidence for the epidermal growth factor receptor as a target for lung cancer prevention. Clin Cancer Res 8(1):54-60

    PubMed  CAS  Google Scholar 

  137. Izzo JG, Papadimitrakopoulou VA, Liu DD et al (2003) Cyclin D1 genotype, response to biochemoprevention, and progression rate to upper aerodigestive tract cancer. J Natl Cancer Inst 95(3):198-205

    PubMed  CAS  Google Scholar 

  138. Petty WJ, Dragnev KH, Memoli VA et al (2004) Epidermal growth factor receptor tyrosine kinase inhibition represses cyclin D1 in aerodigestive tract cancers. Clin Cancer Res 10(22):7547-7554

    PubMed  CAS  Google Scholar 

  139. Pitha-Rowe I, Petty WJ, Feng Q et al (2004) Microarray analyses uncover UBE1L as a candidate target gene for lung cancer chemoprevention. Cancer Res 64(21):8109-8115

    PubMed  CAS  Google Scholar 

  140. Dragnev KH, Pitha-Rowe I, Ma Y et al (2004) Specific chemopreventive agents trigger proteasomal degradation of G1 cyclins: implications for combination therapy. Clin Cancer Res 10(7):2570-2577

    PubMed  CAS  Google Scholar 

  141. Sueoka N, Lee HY, Wiehle S et al (2000) Insulin-like growth factor binding protein-6 activates programmed cell death in non-small cell lung cancer cells. Oncogene 19(38):4432-4436

    PubMed  CAS  Google Scholar 

  142. Lee HY, Moon H, Chun KH et al (2004) Effects of insulin-like growth factor binding protein-3 and farnesyltransferase inhibitor SCH66336 on Akt expression and apoptosis in non-small-cell lung cancer cells. J Natl Cancer Inst 96(20):1536-1548

    PubMed  CAS  Google Scholar 

  143. Pold M, Krysan K, Pold A et al (2004) Cyclooxygenase-2 modulates the insulin-like growth factor axis in non-small-cell lung cancer. Cancer Res 64(18):6549-6555

    PubMed  CAS  Google Scholar 

  144. West KA, Linnoila IR, Belinsky SA, Harris CC, Dennis PA (2004) Tobacco carcinogen-induced cellular transformation increases activation of the phosphatidylinositol 3′-kinase/Akt pathway in vitro and in vivo. Cancer Res 64(2):446-451

    PubMed  CAS  Google Scholar 

  145. Tsao AS, McDonnell T, Lam S et al (2003) Increased phospho-AKT (Ser(473)) expression in bronchial dysplasia: implications for lung cancer prevention studies. Cancer Epidemiol Biomarkers Prev 12(7):660-664

    PubMed  CAS  Google Scholar 

  146. Chun KH, Kosmeder JW 2nd, Sun S et al (2003) Effects of deguelin on the phosphatidylinositol 3-kinase/Akt pathway and apoptosis in premalignant human bronchial epithelial cells. J Natl Cancer Inst 95(4):291-302

    PubMed  CAS  Google Scholar 

  147. Jyonouchi H, Sun S, Iijima K, Wang M, Hecht SS (1999) Effects of anti-7,8-dihydroxy-9,10-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene on human small airway epithelial cells and the protective effects of myo-inositol. Carcinogenesis 20(1):139-145

    PubMed  CAS  Google Scholar 

  148. Bren-Mattison Y, Van Putten V, Chan D, Winn R, Geraci MW, Nemenoff RA (2005) Peroxisome proliferator-activated receptor-gamma (PPAR(gamma)) inhibits tumorigenesis by reversing the undifferentiated phenotype of metastatic non-small-cell lung cancer cells (NSCLC). Oncogene 24(8):1412-1422

    PubMed  CAS  Google Scholar 

  149. Wick M, Hurteau G, Dessev C et al (2002) Peroxisome proliferator-activated receptor-gamma is a target of nonsteroidal anti-inflammatory drugs mediating cyclooxygenase-independent inhibition of lung cancer cell growth. Mol Pharmacol 62(5):1207-1214

    PubMed  CAS  Google Scholar 

  150. Govindarajan R, Ratnasinghe L, Simmons DL et al (2007) Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. J Clin Oncol 25(12):1476-1481

    PubMed  CAS  Google Scholar 

  151. Hazra S, Batra RK, Tai HH, Sharma S, Cui X, Dubinett SM (2007) Pioglitazone and rosiglitazone decrease prostaglandin E2 in non-small-cell lung cancer cells by up-regulating 15-hydroxyprostaglandin dehydrogenase. Mol Pharmacol 71(6):1715-1720

    PubMed  CAS  Google Scholar 

  152. Nemenoff R, Meyer AM, Hudish TM et al (2008) Prostacyclin prevents murine lung cancer independent of the membrane receptor by activation of peroxisomal proliferator - activated receptor gamma. Cancer Prev Res (Phila Pa) 1(5):349-356

    CAS  Google Scholar 

  153. Han S, Rivera HN, Roman J (2005) Peroxisome proliferator-activated receptor-gamma ligands inhibit alpha5 integrin gene transcription in non-small cell lung carcinoma cells. Am J Respir Cell Mol Biol 32(4):350-359

    PubMed  CAS  Google Scholar 

  154. Chang TH, Szabo E (2002) Enhanced growth inhibition by combination differentiation therapy with ligands of peroxisome proliferator-activated receptor-gamma and inhibitors of histone deacetylase in adenocarcinoma of the lung. Clin Cancer Res 8(4):1206-1212

    PubMed  CAS  Google Scholar 

  155. Blaine SA, Meyer AM, Hurteau G et al (2005) Targeted over-expression of mPGES-1 and elevated PGE2 production is not sufficient for lung tumorigenesis in mice. Carcinogenesis 26(1):209-217

    PubMed  CAS  Google Scholar 

  156. Belinsky SA (2005) Silencing of genes by promoter hypermethylation: key event in rodent and human lung cancer. Carcinogenesis 26(9):1481-1487

    PubMed  CAS  Google Scholar 

  157. Suzuki M, Sunaga N, Shames DS, Toyooka S, Gazdar AF, Minna JD (2004) RNA interference-mediated knockdown of DNA methyltransferase 1 leads to promoter demethylation and gene re-expression in human lung and breast cancer cells. Cancer Res 64(9):3137-3143

    PubMed  CAS  Google Scholar 

  158. Desai D, Das A, Cohen L, el-Bayoumy K, Amin S (2003) Chemopreventive efficacy of suberoylanilide hydroxamic acid (SAHA) against 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-induced lung tumorigenesis in female A/J mice. Anticancer Res 23(1A):499-503

    PubMed  CAS  Google Scholar 

  159. Wang S, Yan-Neale Y, Fischer D et al (2003) Histone deacetylase 1 represses the small GTPase RhoB expression in human nonsmall lung carcinoma cell line. Oncogene 22(40):6204-6213

    PubMed  CAS  Google Scholar 

  160. Suh YA, Lee HY, Virmani A et al (2002) Loss of retinoic acid receptor beta gene expression is linked to aberrant histone H3 acetylation in lung cancer cell lines. Cancer Res 62(14):3945-3949

    PubMed  CAS  Google Scholar 

  161. Youssef EM, Lotan D, Issa JP et al (2004) Hypermethylation of the retinoic acid receptor-beta(2) gene in head and neck carcinogenesis. Clin Cancer Res 10(5):1733-1742

    PubMed  CAS  Google Scholar 

  162. Zhu WG, Lakshmanan RR, Beal MD, Otterson GA (2001) DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors. Cancer Res 61(4):1327-1333

    PubMed  CAS  Google Scholar 

  163. Zou CP, Kurie JM, Lotan D, Zou CC, Hong WK, Lotan R (1998) Higher potency of N-(4-hydroxyphenyl)retinamide than all-trans-retinoic acid in induction of apoptosis in non-small cell lung cancer cell lines. Clin Cancer Res 4(5):1345-1355

    PubMed  CAS  Google Scholar 

  164. Belinsky SA, Klinge DM, Stidley CA et al (2003) Inhibition of DNA methylation and histone deacetylation prevents murine lung cancer. Cancer Res 63(21):7089-7093

    PubMed  CAS  Google Scholar 

  165. Suzuki S, Higuchi M, Proske RJ, Oridate N, Hong WK, Lotan R (1999) Implication of mitochondria-derived reactive oxygen species, cytochrome C and caspase-3 in N-(4-hydroxyphenyl)retinamide-induced apoptosis in cervical carcinoma cells. Oncogene 18(46):6380-6387

    PubMed  CAS  Google Scholar 

  166. Sun SY, Schroeder CP, Yue P, Lotan D, Hong WK, Lotan R (2005) Enhanced growth inhibition and apoptosis induction in NSCLC cell lines by combination of celecoxib and 4HPR at clinically relevant concentrations. Cancer Biol Ther 4(4):407-413

    PubMed  CAS  Google Scholar 

  167. Sun SY, Hail N Jr, Lotan R (2004) Apoptosis as a novel target for cancer chemoprevention. J Natl Cancer Inst 96(9):662-672

    PubMed  CAS  Google Scholar 

  168. Guerrieri-Gonzaga A, Robertson C, Bonanni B et al (2006) Preliminary results on safety and activity of a randomized, double-blind, 2 x 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in premenopausal women. J Clin Oncol 24(1):129-135

    PubMed  CAS  Google Scholar 

  169. Lippman SM, Lee JJ, Sabichi AL (1998) Cancer chemoprevention: progress and promise. J Natl Cancer Inst 90(20):1514-1528

    PubMed  CAS  Google Scholar 

  170. Seki Y, Suzuki N, Imaizumi M et al (2004) STAT3 and MAPK in human lung cancer tissues and suppression of oncogenic growth by JAB and dominant negative STAT3. Int J Oncol 24(4):931-934

    PubMed  CAS  Google Scholar 

  171. Liu X, Yue P, Zhou Z, Khuri FR, Sun SY (2004) Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells. J Natl Cancer Inst 96(23):1769-1780

    PubMed  CAS  Google Scholar 

  172. Lubet RA, Zhang Z, Wang Y, You M (2004) Chemoprevention of lung cancer in transgenic mice. Chest 125(5 Suppl):144S-147S

    PubMed  CAS  Google Scholar 

  173. Dauer DJ, Ferraro B, Song L et al (2005) Stat3 regulates genes common to both wound healing and cancer. Oncogene 24(21):3397-3408

    PubMed  CAS  Google Scholar 

  174. Swanton C (2004) Cell-cycle targeted therapies. Lancet Oncol 5(1):27-36

    PubMed  CAS  Google Scholar 

  175. Wislez M, Spencer ML, Izzo JG et al (2005) Inhibition of mammalian target of rapamycin reverses alveolar epithelial neoplasia induced by oncogenic K-ras. Cancer Res 65(8):3226-3235

    PubMed  CAS  Google Scholar 

  176. Abbruzzese JL, Lippman SM (2004) The convergence of cancer prevention and therapy in early-phase clinical drug development. Cancer Cell 6(4):321-326

    PubMed  CAS  Google Scholar 

  177. Keith R et al. (2009) Oral Iloprost improves endobronchial dysplasia in formers smokers. J Thorac Oncol IASLC meeting; #7753

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pulmonary Medicine and Medical Oncology, University of Colorado Denver, 12801 E 17th Ave, Aurora, CO, 80045, USA

    Nir Peled, Robert L. Keith & Fred R. Hirsch

Authors
  1. Nir Peled
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert L. Keith
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Fred R. Hirsch
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nir Peled .

Editor information

Editors and Affiliations

  1. M. D. Anderson Cancer Center, University of Texas, Holcombe Blvd. 1515, Houston, 77030, U.S.A.

    David J. Stewart

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Humana Press, a part of Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Peled, N., Keith, R.L., Hirsch, F.R. (2010). Lung Cancer Prevention. In: Stewart, D. (eds) Lung Cancer. Current Clinical Oncology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60761-524-8_5

Download citation

  • DOI: https://doi.org/10.1007/978-1-60761-524-8_5

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-60761-523-1

  • Online ISBN: 978-1-60761-524-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation